sickle cell disease

Editas to lay off staff after search for sickle cell partner comes up empty
BioPharma Dive
Thu, 12/12/24 - 11:52 pm
Editas Medicine
sickle cell disease
layoffs
reni-cel
Gene therapy uptake in sickle cell stays slow, despite patient interest
BioPharma Dive
Mon, 12/9/24 - 10:37 am
gene therapy
sickle cell disease
patients
Casgevy
Lyfgenia
Bluebird Bio
Vertex Pharmaceuticals
Beam hits hemoglobin goal in first base editing clinical data, reports death tied to conditioning drug
Fierce Biotech
Tue, 11/5/24 - 10:05 am
Beam Therapeutics
clinical trials
sickle cell disease
CRISPR
base editing
Editas, changing course again, looks to partner lead CRISPR therapy
BioPharma Dive
Tue, 10/22/24 - 11:45 am
Editas Medicine
gene editing
CRISPR
reni-cel
sickle cell disease
beta thalassemia
Sickle cell community scrambles to find safe plan after a drug is pulled from the market
Stat
Mon, 09/30/24 - 09:56 am
Pfizer
sickle cell disease
Oxbryta
patients
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Fierce Pharma
Wed, 09/25/24 - 10:29 pm
Pfizer
sickle cell disease
Oxbryta
Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia
Fierce Pharma
Wed, 08/14/24 - 10:31 pm
Bluebird Bio
sickle cell disease
Vertex Pharmaceuticals
Lyfgenia
Casgevy
Vertex presents longer-term data that shows durability and consistency of Casgevy
Fierce Pharma
Fri, 06/14/24 - 11:30 am
Vertex Pharmaceuticals
sickle cell disease
FDA
Casgevy
First Patient Begins Newly Approved Sickle Cell Gene Therapy
NY Times, NY
Mon, 05/6/24 - 11:40 am
Bluebird Bio
gene therapy
sickle cell disease
patients
Lyfgenia
Pfizer Terminates Phase III Sickle Cell Study Due to Slow Patient Recruitment
BioSpace
Wed, 03/27/24 - 10:58 am
Pfizer
sickle cell disease
inclacumab
clinical trials
Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch
BioSpace
Tue, 03/19/24 - 11:22 am
Bluebird Bio
funding
sickle cell disease
Lyfgenia
Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
BioSpace
Thu, 03/14/24 - 06:19 pm
Vertex Pharmaceuticals
UK
sickle cell disease
CRISPR
Casgevy
Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan
Fierce Pharma
Mon, 03/11/24 - 11:33 am
Bluebird Bio
Michigan
lovo-cel
Lyfgenia
Medicaid
sickle cell disease
gene therapy
Sickle Cell Gene Therapies Seen as Cost Effective Below $2M Threshold: Study
BioSpace
Tue, 01/23/24 - 11:18 am
gene therapy
sickle cell disease
drug pricing
Vertex Pharmaceuticals
Bluebird Bio
Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal
Fierce Pharma
Thu, 01/4/24 - 11:37 am
Bluebird Bio
Lyfgenia
sickle cell disease
gene therapy
Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning
BioSpace
Mon, 12/11/23 - 11:20 am
Bluebird Bio
sickle cell disease
Lyfgenia
gene therapy
CRISPR
FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR's halo?
Fierce Pharma
Sun, 12/10/23 - 11:15 pm
Bluebird Bio
sickle cell disease
FDA
CRISPR
Lyfgenia
ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets
Fierce Biotech
Sun, 12/10/23 - 11:12 pm
Pfizer
sickle cell disease
ASH
marstacimab
In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease
Stat
Fri, 12/8/23 - 11:36 am
Vertex Pharmaceuticals
FDA
CRISPR
gene editing
Casgevy
sickle cell disease
FDA Could Approve First CRISPR Treatment Today That Might Cure Sickle Cell
Forbes
Fri, 12/8/23 - 09:54 am
Vertex Pharmaceuticals
Casgevy
FDA
CRISPR
sickle cell disease

Pages